Table 1.
Clinical demographics
| Case ID | Disease course | Age | Sex | Disease duration (months) | Progressive phase duration (months) | MS-related treatment | Cause of death |
|---|---|---|---|---|---|---|---|
| MS 1 | AMS | 78 | M | 2 | – | No | MSR |
| MS 2 | AMS | 34 | F | 4 | – | S | MSR |
| MS 3 | AMS | 45 | M | 0.2 | – | S | MSR |
| MS 4 | AMS | 69 | F | 2 | – | S | MSR |
| MS 5 | AMS | 35 | M | 1.5 | – | S | MSR |
| MS 6 | AMS | 45 | M | 1,5 | – | S | MSR |
| MS 7 | RRMS | 40 | F | 120 | – | S | UK |
| MS 8 | SPMS | 41 | M | 137 | 99 | Mit, IFNβ, S | CV |
| MS 9 | SPMS | 34 | M | 120 | n.a. | No | UK |
| MS 10 | SPMS | 42 | F | 241 | 87 | No | UK |
| MS 11 | SPMS | 53 | F | 241 | 104 | S | P |
| MS 12 | SPMS | 62 | F | 144 | n.a. | S | P |
| MS 13 | SPMS | 48 | F | 410 | 182 | No | UK |
| MS 14 | SPMS | 46 | F | 444 | 228 | No | CV |
| MS 15 | SPMS | 56 | M | 372 | 132 | No | CV |
| MS 16 | SPMS | 59 | F | 492 | 168 | S | CV |
| MS 17 | PPMS | 55 | F | 60 | 60 | No | PE |
| MS 18 | PPMS | 36 | M | 61 | 61 | No | PE |
| MS 19 | PPMS | 71 | F | 264 | 264 | No | PE |
| MS 20 | PPMS | 53 | M | 168 | 168 | No | CV |
| MS 21 | PPMS | 77 | F | 168 | 168 | No | CV |
| MS 22 | PPMS | 67 | M | 87 | 87 | No | CV |
| MS 23 | PPMS | 54 | F | 72 | 72 | No | CV |
| Control 1 | Control | 39 | F | – | – | – | |
| Control 2 | Control | 36 | F | – | – | – | |
| Control 3 | Control | 46 | M | – | – | – | |
| Control 4 | Control | 45 | F | – | – | – | |
| Control 5 | Control | 47 | F | – | – | – | |
| Control 6 | Control | 29 | F | – | – | – | |
| Control 7 | Control | 57 | M | – | – | – | |
| Control 8 | Control | 42 | F | – | – | – | |
| Control 9 | Control | 46 | M | – | – | – | |
| Control 10 | Control | 72 | M | – | – | – | |
| Control 11 | Control | 65 | M | – | – | – | |
| Control 12 | Control | 67 | M | – | – | – | |
| Control 13 | Control | 73 | M | – | – | – | |
| Control 14 | Control | 71 | F | – | – | – | |
| Control 15 | Control | 80 | F | – | – | – | |
| Control 16 | Control | 84 | F | – | – | – | |
| PML + fumarate 1 | PML | 77 | M | – | – | Fumarates for psoriasis | Brain biopsy |
| PML + fumarate 2 | PML | 68 | M | – | – | Fumarates for psoriasis | Brain biopsy |
| PML control 1 | PML | 60 | M | – | – | – | Brain biopsy |
| PML control 2 | PML | 85 | M | – | – | – | Brain biopsy |
| Septic control 1 | Septic control | 97 | F | – | – | – | |
| Septic control 2 | Septic control | 37 | M | – | – | – | |
| Septic control 3 | Septic control | 71 | F | – | – | – | |
| Septic control 4 | Septic control | 45 | M | – | – | – | |
| Septic control 5 | Septic control | 74 | M | – | – | – | |
| Septic control 6 | Septic control | 51 | F | – | – | – | |
| Septic control 7 | Septic control | 70 | M | – | – | – | |
| Septic control 8 | Septic control | 71 | M | – | – | – | |
| Septic control 9 | Septic control | 95 | F | – | – | – | |
| Septic control 10 | Septic control | 42 | F | – | – | – | |
| Septic control 11 | Septic control | 89 | F | – | – | – | |
| Septic control 12 | Septic control | 79 | F | – | – | – |
MS multiple sclerosis, AMS acute multiple sclerosis, RRMS relapsing–remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, PPMS primary progressive multiple sclerosis, F female, M male, n.a. not available
MS-related treatment (last month before death): No no immunosuppressive or immunomodulatory therapy; S steroids, Mitox mitoxantrone; IFN-β β-interferon
Cause of death: MSR directly MS related, CV cardiovascular, PE pulmonary embolism, P pneumonia, UK unknown